

DR. RAM MANOHAR LOHIA INSTITUTE OF MEDICAL SCIENCES

VIBHUTI KHAND, GOMTI NAGAR, LUCKNOW-10(U.P)

Phone No: - 0522-4918502, 4918510 E-Mail id: hrftendercell@gmail.com

1291

Ref No: HRF/PAC/2025

Dated: 18Sept. 2025

Notice

Sub:- Procurement of following items on proprietary/ single quotation basis for different department

The Dr. RMLIMS, Lucknow intend to procure following item (s) manufactured as per mentioned against item name for **Serplulimab concentrate for solution for infusion 100mg/10ml vial** on proprietary/single quotation basis from their authorized dealer/seller as per enclosed Technical Specifications.

SI Product details		Principle Company	Subsidiary Company	Authorised Seller/	
no		(Manufacturer)	(Marketing)	Company/Dealer	
1	Serplulimab	M/s Shanghai Henlius	M/s Intas	M/s Sakun Sales Pvt,	
	concentrate for	Biopharmaceuticals co.,	Pharmaceuticals	Ltd, Lucknow-226018	
	solution for	Ltd, (Building D) Block	Limited, Plot		
	infusion	1, No. 1289 Yishan	No.423/P/A, Sarkhej –		
	100mg/10ml vial	Road, Xuhui district-	Bavla Highway, Village		
		200233 Shanghai	–Moraiya, Gujrat,		
		(China).	Sanand, Ahemdabad-		
			382213 (India)		

The Proprietary Certificate for above items (s) submitted by principle company or their authorized seller/ Company/ Dealer is attached. The above documents are being uploaded for open information to all manufacturer/ supplier to submit comments / objections/ representation on the chairmen. (HRF), Dr RMLIMS, Lucknow on email id hrftendercell@gmail.com, from the date mentioned above, falling which it will be presumed that no other supplier is having any comment to offer and the case will be decided on merits. The comments/objection/representation to be submitted on the following:-

- (i) Weather the above medicine/surgical items is manufactured by any other manufacture other than as per mentioned principle company or their Authorized seller/company/Dealer.
- (ii) Fulfill all the parameter(s) as per technical specifications.

Encl: - Related documents enclosed.

- (1) HRF Requisition form
- (2) PAC Certification of company letter.
- (3) Authorization from company letter.

Chairman (HRF)
Dr. RMLIMS, Lucknow

HRF Requisition Form
Request for new items/upgraded version
(Drugs, Consumables & Disinfectants)

4	n in a new depression					
	Name of item (generic name only, no brand name) SERPLULIMAB 100 MG 2;					
	Please note that if another brand of the same item is already available in HRF.					
	the request will not be entertained for another brand.					
	2. Quantity needed (Per month)					
	3 Probable Source (1) Inters Pharmaceuticals Ltd.					
	-(II)					
	(111)					
	(If only one source please sign. The P-3 Form on back page)					
	4 Similar item available In HRF inventory? -Yes/No					
	5. If yes then, why this item?					
	6. Do you want this item to be made available on regular basis -Yes/No					
	7. If yes, then what will be the monthly consumption of this item?					
	8. Is same item in single unit be used on many patients ? If yes then specify the					
	Number of times/Number of patients, the unit will be used					
	9. Will it be a part of any procedure (Dossier, please specify the name of					
	procedure					
	10. If it is an upgraded version of an existing item in HRF inventory, do you want old					
	version to continue?Yes/No					
	11 Justification for new requisition It is 1st Anti PD-1 immuno the saft					
	approved for ES-SCLC 1st Line treatment.					
13	N. Karr					
	2. Catebran Singh					
	Dr. Sakstram Singn Assistant Provisor (Norted Decology) Assistant Provisor (Norted Decology) Month of Nedmess lav (Friday Month of Nedmess lav (Friday					
	Mondan Wednesslav i Friday					
	Mondan Wednesday Friday					
5	(Signature of Head on Department)					
	DR. ROLINI KHURANA SETHI					
470.4	MD, MAMS, FICRO					
the	The state was the processed for short-term rate contract, this way happony					
cili	out 1-2 months time					

Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow

PROPRIETARY ARTICLE CERTIFICATE

It is certified that the items required should be purchased from M/sShakun.
Salus Pvt Ltd: Who are the sole manufacture/agents of the sole manufacturers M/s Intas Pharmaccuticals Ltd.
Similar items manufactured by other firm(s) shall not be suitable for our purpose for
the following reasons: -
No other firm is manufacturing Similar
Product. Only Intus Pharmaceuticals Ltd is
marketing. His Omduct in India.

Dr. Salesam Singh Assistant rolessor (Medical Oncology) MD.DM. Fellow BMT MD.DM. Fellow BMT Signature of Indenter

Requisition No:

Department

Dated

DR. ROHINIKHURANA SETHI

Designation RCRO

Signfexible addition Oncology

DEPARTMENTALS DOTTO OGY
Dr. R.M.L.I.M.S., Lucknow



INTAS PHARMACEUTICALS LIMITED

Factory: Plot No. 457, 458, Vill. Matoda and Plot No. 191/218 P, Vill. Chacharwadi, Sarkhej Bavla Highway Road, Tal.: Sanand, Dist. Ahmedabad

Date: 06.08.2025

IPL/QTN/ARB/25-26/8099

To,
The SPO, Lucknow,
RML Hospital
LUCKNOW.

Sub: Rate Quotation

Dear Sir/Madam,

Please find here with our Rate Quotation to your premier institute as per Annexure I,

- 1. The rates are exclusive of all taxes.
- Products will be supplied through our authorized distributor M/s. Shakun Sales Pvt Ltd, Lucknow,, against confirm of purchase order copy from institution.
- 3. Supply of Order is subject to availability of stocks.
- **4.** We have offered very special Rate to your Institute. In such case, we shall not accept any expiry & replacement for special rate products.
- If there is any change in MRP, the quoted rate to hospital will also change proportionally. In case of Super Speciality products, quoted rate will remain same.
- 6. All previous quotation & letter of authorisation stand null and void.
- 7. This Quotation is valid till 31.03.2026.

Looking forward to have a long term Business Relationship and valuable orders.

For Intas Pharmaceuticals Limited

Abhishek Bajaj Authorized Signature

abhishek_bajaj@intaspharma.com

*"We respect the intellectual property of the innovator company. The goods as above will be supplied for commercial purpose only after the relevant patent expiry."



INTAS PHARMACEUTICALS LIMITED

Corporate House: Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad – 380054, Gujarat, INDIA. Tel.: 079-61577000, Website: http://www.intaspharma.com CIN - U24231GJ1985PLC007866

Factory: Plot No. 457, 458, Vill. Matoda and Plot No. 191/218 P, Vill. Chacharwadi, Sarkhej Bavla Highway Road, Tal.: Sanand, Dist. Ahmedabad.

TO WHOMSOEVER IT MAY CONCERN

Sub: PROPRIETARY ARTICLE CERTIFICATE

Dear Sir,

This is to certify and confirm that Serplulimab Concentrate for Solution for Infusion 100mg/10 ml Vial is manufactured by Shanghai Henlius Biopharmaceutical Co., Ltd, and it is their proprietary and patented product.

Intas Pharmaceuticals Ltd. is sole importer and Marketer for this product in India

Details of product is as under:

No.	Brand Name	Generic Name	Pack
1	HETRONIFLY 10mg/ml (1 VIAL)	Serplulimab Concentrate for Solution for Infusion 100mg/10 ml Vial	1 Vial

Details of import license copy, Pack shot and literature are attached.

It is further certified that no other company can market the said product, in India.

Thanking you.

For Intas Pharmaceuticals Limited

MIGH

Abhishek R Bajaj

Authorized Signatory

abhishek_bajaj@intaspharma.com

Q Henlius

PROPRIETARY ARTICLE CERTIFICATE

To Whom It May Concern,

This is to certify that Serplulimab Concentrate for Solution for Infusion 100 mg/10 ml vial (Brand name: Hetronifly) ("Serplulimab") is a novel monoclonal antibody product researched and developed by Shanghai Henlius Biotech, Inc. ("Henlius"). Serplulimab is protected by intellectual property rights and is subject to patent applications, as detailed below.

The following patent applications are relevant to Serplulimab in India:

- IN201917015159: patent application covering the amino acid sequences of the Complementarity-Determining Regions (CDRs) of Serplulimab.
 - o Status: Application under examination
 - o Expected expiry: September 2037
- 2. IN202247044124: patent application covering the approved formulation of Serplulimab.
 - o Status: Application under examination
 - Expected expiry: January 2041

Henlius has granted exclusive commercialization rights for Serplulimab in India to Intas Pharmaceuticals Ltd. ("Intas"), with corporate domicile at Corporate House, S G Highway, Thaltej, Ahmedabad 380054, India, in accordance with the License Agreement between Henlius and Intas dated October 27, 2023.

Sincerely,

Shanghai Henlius Biotech Inc.

Name: Jun ZHU

Title: Legal Representative



GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation

Ministry of Health & Family Welfare FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

REGISTRATION CERTIFICATE TO BE ISSUED FOR IMPORT OF DRUGS INTO INDIA UNDER DRUGS **AND COSMETICS RULES 1945**

Registration Certificate No. RC/BIO-000489

1. M/s. Shanghai Henlius Biopharmaceutical Co., Ltd., (Building D) Block 1, No. 1289 Yishan Road, Xuhui district . - 200233 Shanghai (China) having factory premises at M/s. Shanghai Henlius Biopharmaceutical Co., Ltd., (Building D) Block 1, No. 1289 Yishan Road, Xuhui district Shanghai . (China) - 200233 [Manufacturing Site, Primary Packaging Site, Secondary Packaging Site, Batch Release has been registered under Rule 27-A as a manufacturer and is hereby issued this Site, Testing Site Registration Certificate.

- NO ARD CO

- 2. Name(s) of drug(s), which may be imported under this Registration Certificate(Please refer the enclosed list of drugs).
- 3. This Registration Certificate shall be in force from 16-Jun-2025 to 15-Jun-2028 unless it is sooner suspended or cancelled under the rules.
- 4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/s M/s Intas Pharmaceuticals Limited, Plot No. 423/P/A, Sarkhej-Bavla Highway, Village Sanand, Ahmedabad- 382213 (India) who will be responsible for the business - Moraiya,, Gujarat, activities of the manufacturer in India in all respects.
- 5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi Date:16-Jun-2025



RAJEEV SINGH

Digitally signed by RAJEEV SINGH RAGHUVANSHI RAGHUVANSHI Date: 2025.06.16 17:12:28

> LICENSING AUTHORITY Seal/Stamp